EPAS1 and nonpapillary renal cell carcinoma: The currently used first‐line drug in the treatment of ccRCC, sunitinib, is a class of drugs targeting the family of vascular endothelial growth factor receptors and platelet‐derived growth factor receptors, which are important downstream targets of HIF2a.45, 46, 47